Search research articles

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A comprehensive pharmacological survey across heterogeneous patient-derived glioblastoma stem cell models.

iScience·2026

Same author

Identification of drug candidates against glioblastoma with machine learning and high-throughput screening of heterogeneous cellular models.

Digital discovery·2026

Same author

Discovery of a Highly Potent and Selective mTOR Inhibitor that Strongly Suppresses Glioblastoma Multiforme Cell Growth.

Journal of medicinal chemistry·2026

Same author

Progress and new challenges in image-based profiling.

Molecular systems biology·2026

Same author

High-throughput 3D phenotypic screening identifies repurposed MEK inhibitors as drivers of chondrogenesis for cartilage regeneration.

Frontiers in bioengineering and biotechnology·2026

Same author

High content 3D imaging by dual-view oblique plane microscopy.

PNAS nexus·2025

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Jan 2, 2026

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Drug Screening Platforms and RPPA.

John C Dawson¹, Scott J Warchal¹, Neil O Carragher²

¹Cancer Research UK Edinburgh Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, Scotland, UK.

Advances in Experimental Medicine and Biology

|December 11, 2019

Summary

This summary is machine-generated.

Reverse phase protein array (RPPA) is a versatile tool for drug discovery, enabling precise protein quantification. Its integration with advanced bioinformatics and screening platforms drives a new era of evidence-led drug development.

Keywords:

Biomarkers Drug combinations Mechanism-of-action Pharmacology Phenotypic screening

More Related Videos

Identifying Protein-protein Interaction Sites Using Peptide Arrays

Identifying Protein-protein Interaction Sites Using Peptide Arrays

Published on: November 18, 2014

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Related Experiment Videos

Last Updated: Jan 2, 2026

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Identifying Protein-protein Interaction Sites Using Peptide Arrays

Identifying Protein-protein Interaction Sites Using Peptide Arrays

Published on: November 18, 2014

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Area of Science:

Biotechnology
Drug Discovery
Proteomics

Background:

Reverse phase protein array (RPPA) offers scalable and cost-effective protein quantification for large sample sets.
RPPA has been instrumental in various drug discovery applications, including target screening, toxicity assessment, and biomarker discovery.

Purpose of the Study:

To discuss the evolution of drug discovery strategies.
To highlight the role of RPPA in modern drug discovery.
To demonstrate how RPPA integrates with emerging platforms for enhanced drug development.

Main Methods:

Review of RPPA applications in drug discovery.
Discussion of technological advancements in high-throughput screening and bioinformatics.
Integration of RPPA with other screening platforms and computational approaches.

Main Results:

RPPA facilitates primary and secondary screening, mechanism-of-action profiling, and biomarker discovery.
Advances in bioinformatics and computational analysis enhance drug target identification and validation.
Integration of RPPA with other platforms leads to more informative drug discovery.

Conclusions:

RPPA is a key technology in contemporary drug discovery.
The synergy between RPPA, advanced screening technologies, and bioinformatics fuels more effective drug development.
This integrated approach supports a new paradigm of evidence-led drug discovery strategies.